Briciclib

865783-99-9

C19H23O10PS

DMSO : >= 31 mg/mL (65.34 mM)

Cell Cycle/DNA Damage

Briciclib is a water soluble derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers. IC50 & Target: eIF4E^[1] In Vitro: Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI₅₀s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours^[1].